1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Renzoni, D.A. Pugh, D.J.R. Siligardi, G. Das, P. Morton, C.J. Rossi, C. Waterfield, M.D. Campbell, I.D. Ladbury, J.E. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 1 90.00 90.00 90.00 1.000 1.000 1.000 C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C11 H12 N2 O2 204.225 y TRYPTOPHAN L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking US Biochemistry BICHAW 0033 0006-2960 35 15646 15653 10.1021/bi9620969 8961927 Structural and thermodynamic characterization of the interaction of the SH3 domain from Fyn with the proline-rich binding site on the p85 subunit of PI3-kinase. 1996 UK Structure STRUE6 2005 0969-2126 4 705 Solution Structure and Peptide Binding of the SH3 Domain from Human Fyn 1996 10.2210/pdb1azg/pdb pdb_00001azg 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 1405.640 PRO-PRO-ARG-PRO-LEU-PRO-VAL-ALA-PRO-GLY-SER-SER-LYS-THR P85 SUBUNIT OF PI3-KINASE, RESIDUES 91 - 104 1 man polymer 7554.108 FYN 2.7.1.112 SH3 DOMAIN, RESIDUES 82 - 148 N-TERMINAL GS FROM EXPRESSION SYSTEM 1 man polymer P2L no no PPRPLPVAPGSSKT PPRPLPVAPGSSKT A polypeptide(L) no no TGVTLFVALYDYEARTEDDLSFHKGEKFQILNSSEGDWWEARSLTTGETGYIPSNYVAPVDSIQAEE TGVTLFVALYDYEARTEDDLSFHKGEKFQILNSSEGDWWEARSLTTGETGYIPSNYVAPVDSIQAEE B polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n human Homo Escherichia Escherichia coli sample BL21 9606 Homo sapiens 469008 Escherichia coli BL21(DE3) BL21 (DE3) PGEX database_2 pdbx_database_status pdbx_struct_assembly pdbx_struct_oper_list repository Initial release Version format compliance Version format compliance Database references Derived calculations Other 1 0 1998-02-25 1 1 2008-03-03 1 2 2011-07-13 1 3 2022-02-16 _database_2.pdbx_DOI _database_2.pdbx_database_accession _pdbx_database_status.process_site Y BNL 1997-11-18 REL 50 1 REFINEMENT DETAILS CAN BE FOUND IN THE JRNL CITATION ABOVE. BRUNGER refinement X-PLOR 3.1 PRO 91 n 1 PRO 91 A PRO 92 n 2 PRO 92 A ARG 93 n 3 ARG 93 A PRO 94 n 4 PRO 94 A LEU 95 n 5 LEU 95 A PRO 96 n 6 PRO 96 A VAL 97 n 7 VAL 97 A ALA 98 n 8 ALA 98 A PRO 99 n 9 PRO 99 A GLY 100 n 10 GLY 100 A SER 101 n 11 SER 101 A SER 102 n 12 SER 102 A LYS 103 n 13 LYS 103 A THR 104 n 14 THR 104 A n 1 82 B n 2 83 B VAL 84 n 3 VAL 84 B THR 85 n 4 THR 85 B LEU 86 n 5 LEU 86 B PHE 87 n 6 PHE 87 B VAL 88 n 7 VAL 88 B ALA 89 n 8 ALA 89 B LEU 90 n 9 LEU 90 B TYR 91 n 10 TYR 91 B ASP 92 n 11 ASP 92 B TYR 93 n 12 TYR 93 B GLU 94 n 13 GLU 94 B ALA 95 n 14 ALA 95 B ARG 96 n 15 ARG 96 B THR 97 n 16 THR 97 B GLU 98 n 17 GLU 98 B ASP 99 n 18 ASP 99 B ASP 100 n 19 ASP 100 B LEU 101 n 20 LEU 101 B SER 102 n 21 SER 102 B PHE 103 n 22 PHE 103 B HIS 104 n 23 HIS 104 B LYS 105 n 24 LYS 105 B GLY 106 n 25 GLY 106 B GLU 107 n 26 GLU 107 B LYS 108 n 27 LYS 108 B PHE 109 n 28 PHE 109 B GLN 110 n 29 GLN 110 B ILE 111 n 30 ILE 111 B LEU 112 n 31 LEU 112 B ASN 113 n 32 ASN 113 B SER 114 n 33 SER 114 B SER 115 n 34 SER 115 B GLU 116 n 35 GLU 116 B GLY 117 n 36 GLY 117 B ASP 118 n 37 ASP 118 B TRP 119 n 38 TRP 119 B TRP 120 n 39 TRP 120 B GLU 121 n 40 GLU 121 B ALA 122 n 41 ALA 122 B ARG 123 n 42 ARG 123 B SER 124 n 43 SER 124 B LEU 125 n 44 LEU 125 B THR 126 n 45 THR 126 B THR 127 n 46 THR 127 B GLY 128 n 47 GLY 128 B GLU 129 n 48 GLU 129 B THR 130 n 49 THR 130 B GLY 131 n 50 GLY 131 B TYR 132 n 51 TYR 132 B ILE 133 n 52 ILE 133 B PRO 134 n 53 PRO 134 B SER 135 n 54 SER 135 B ASN 136 n 55 ASN 136 B TYR 137 n 56 TYR 137 B VAL 138 n 57 VAL 138 B ALA 139 n 58 ALA 139 B PRO 140 n 59 PRO 140 B VAL 141 n 60 VAL 141 B n 61 142 B n 62 143 B n 63 144 B n 64 145 B n 65 146 B n 66 147 B n 67 148 B author_defined_assembly 2 dimeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 B O PHE 109 B O PHE 28 B N PHE 87 B N PHE 6 B N VAL 88 B N VAL 7 B O ALA 139 B O ALA 58 B O ASN 113 B O ASN 32 B N GLU 121 B N GLU 40 B N TRP 120 B N TRP 39 B O ILE 133 B O ILE 52 1 B THR 82 B THR 1 1 Y 1 B GLY 83 B GLY 2 1 Y 1 B ASP 142 B ASP 61 1 Y 1 B SER 143 B SER 62 1 Y 1 B ILE 144 B ILE 63 1 Y 1 B GLN 145 B GLN 64 1 Y 1 B ALA 146 B ALA 65 1 Y 1 B GLU 147 B GLU 66 1 Y 1 B GLU 148 B GLU 67 1 Y 1 A ARG 93 0.291 SIDE CHAIN 1 B ARG 123 0.133 SIDE CHAIN 1 A LEU 95 67.31 98.40 1 A PRO 96 -61.17 98.10 1 A ALA 98 -47.51 173.05 1 A PRO 99 -60.78 83.30 1 B THR 85 -152.64 71.58 1 B ALA 95 -56.28 106.10 1 B ASP 100 -64.57 -176.51 1 B PHE 103 -174.58 -172.34 1 B GLU 116 -57.23 -153.36 model building X-PLOR 3.1 refinement X-PLOR 3.1 phasing X-PLOR 3.1 NMR STUDY OF THE SH3 DOMAIN FROM FYN PROTO-ONCOGENE TYROSINE KINASE KINASE COMPLEXED WITH THE SYNTHETIC PEPTIDE P2L CORRESPONDING TO RESIDUES 91-104 OF THE P85 SUBUNIT OF PI3-KINASE, MINIMIZED AVERAGE (PROBMAP) STRUCTURE 1 N N 2 N N B PRO 134 B PRO 53 HELX_P B TYR 137 B TYR 56 5 HA 4 COMPLEX (PHOSPHOTRANSFERASE/PEPTIDE) COMPLEX (PHOSPHOTRANSFERASE-PEPTIDE), SH3 DOMAIN, POLYPROLINE-BINDING, PHOSPHOTRANSFERASE, COMPLEX (PHOSPHOTRANSFERASE-PEPTIDE) complex P85A_HUMAN UNP 1 1 P27986 MSAEGYQYRALYDYKKEREEDIDLHLGDILTVNKGSLVALGFSDGQEARPEEIGWLNGYNETTGERGDFPGTYVEYIGRK KISPPTPKPRPPRPLPVAPGSSKTEADVEQQALTLPDLAEQFAPPDIAPPLLIKLVEAIEKKGLECSTLYRTQSSSNLAE LRQLLDCDTPSVDLEMIDVHVLADAFKRYLLDLPNPVIPAAVYSEMISLAPEVQSSEEYIQLLKKLIRSPSIPHQYWLTL QYLLKHFFKLSQTSSKNLLNARVLSEIFSPMLFRFSAASSDNTENLIKVIEILISTEWNERQPAPALPPKPPKPTTVANN GMNNNMSLQNAEWYWGDISREEVNEKLRDTADGTFLVRDASTKMHGDYTLTLRKGGNNKLIKIFHRDGKYGFSDPLTFSS VVELINHYRNESLAQYNPKLDVKLLYPVSKYQQDQVVKEDNIEAVGKKLHEYNTQFQEKSREYDRLYEEYTRTSQEIQMK RTAIEAFNETIKIFEEQCQTQERYSKEYIEKFKREGNEKEIQRIMHNYDKLKSRISEIIDSRRRLEEDLKKQAAEYREID KRMNSIKPDLIQLRKTRDQYLMWLTQKGVRQKKLNEWLGNENTEDQYSLVEDDEDLPHHDEKTWNVGSSNRNKAENLLRG KRDGTFLVRESSKQGCYACSVVVDGEVKHCVINKTATGYGFAEPYNLYSSLKELVLHYQHTSLVQHNDSLNVTLAYPVYA QQRR FYN_HUMAN UNP 2 1 P06241 GCVQCKDKEATKLTEERDGSLNQSSGYRYGTDPTPQHYPSFGVTSIPNYNNFHAAGGQGLTVFGGVNSSSHTGTLRTRGG TGVTLFVALYDYEARTEDDLSFHKGEKFQILNSSEGDWWEARSLTTGETGYIPSNYVAPVDSIQAEEWYFGKLGRKDAER QLLSFGNPRGTFLIRESETTKGAYSLSIRDWDDMKGDHVKHYKIRKLDNGGYYITTRAQFETLQQLVQHYSERAAGLCCR LVVPCHKGMPRLTDLSVKTKDVWEIPRESLQLIKRLGNGQFGEVWMGTWNGNTKVAIKTLKPGTMSPESFLEEAQIMKKL KHDKLVQLYAVVSEEPIYIVTEYMNKGSLLDFLKDGEGRALKLPNLVDMAAQVAAGMAYIERMNYIHRDLRSANILVGNG LICKIADFGLARLIEDNEYTARQGAKFPIKWTAPEAALYGRFTIKSDVWSFGILLTELVTKGRVPYPGMNNREVLEQVER GYRMPCPQDCPISLHELMIHCWKKDPEERPTFEYLQSFLEDYFTATEPQYQPGENL 91 104 1AZG 91 104 P27986 A 1 1 14 81 147 1AZG 82 148 P06241 B 2 1 67 3 3 anti-parallel anti-parallel anti-parallel anti-parallel B LYS 108 B LYS 27 B LEU 112 B LEU 31 B LEU 86 B LEU 5 B ALA 89 B ALA 8 B VAL 138 B VAL 57 B PRO 140 B PRO 59 B ASN 113 B ASN 32 B SER 114 B SER 33 B TRP 119 B TRP 38 B SER 124 B SER 43 B THR 130 B THR 49 B ILE 133 B ILE 52 1 P 1